Navigation Links
Longevinex exhibits L-shaped safety curve for first time in resveratrol biology
Date:12/29/2010

www.pulsus.com/journals/toc.jsp?sCurrPg=journal&jnlKy=8&fold=Current%20Issue )

Incredulous researchers, at first puzzled by the results of their animal experiment with mice, continued to increase the human equivalent dosage up to 7000 mg, prolonged the duration of the study up to six months, and even administered Longevinex to another animal species, rabbits, with the same results.

Resveratrol antioxidant or pro-oxidant?

In prior animal studies it has been shown that as dosage increases resveratrol shifts from being an antioxidant to a pro-oxidant (promotes oxidation) it binds to copper at low doses and releases copper at high doses. Longevinex exhibited no such toxicity. This remarkable range of safety for any resveratrol-based product has never been demonstrated before.

Animal studies show plain resveratrol is optimally cardio-protective at human-equivalent dose of 100-175 mg and begins to lose its protective effects in a dose as low as 350 mg. Published studies confirm that low-dose resveratrol, particularly when combined with other synergistic small molecules from nature as provided in Longevinex, works better in animal hearts than mega doses.

While this is the first time a resveratrol pill has been demonstrated to exhibit an L-shaped risk curve (risk goes down and stays down at all tested doses), this does not imply that mega-dose Longevinex is totally without side effect at all doses, says Bill Sardi, spokesperson for Longevinex. Consumers should refer to the product label which describes recommended dosage range and potential side effects with resveratrol pills, Sardi says.

Researchers indicate low-dose resveratrol protects the heart from damage should a heart attack occur, while "plain resveratrol should only be used at lower doses as opposite effects can occur higher doses, resulting in adverse effects on health."

Longevinex is the first branded resveratrol product to sh
'/>"/>

Contact: Bill Sardi
bsardi@aol.com
909-596-9507
Resveratrol Partners LLC, dba LONGEVINEX
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Longevinex exerts greater influence over genes than resveratrol
2. Embryonic heart exhibits impressive regenerative capacity
3. GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits
4. GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits
5. Association for Molecular Pathologys 16th Annual Meeting and Exhibits
6. Advance offers revolution in food safety testing
7. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
8. Wake Forest plays integral role in effort to revolutionize vehicle safety
9. Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
10. Musculoskeletal center wins $2.2 million for drug safety
11. New infant formula safety advice could prevent infant suffering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... promising on paper; things are,often very different in reality. ... are supposed to strip the "immortal" (able to,divide indefinitely) ... to block their function, preventing them to inhibit completely,the ... for something,else? Hell no! Look out for whats stopping ...
... Notch pathway ,is an important molecular signaling mechanism whose ... nearly a century since the,identification of a mutant strain ... lab in 1910. Later studies,revealed that the Notch gene ... the cell membrane and which is capable of,interacting with ...
Cached Biology News:GATA: a graphic alignment tool for comparative sequence analysis 2Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
(Date:8/28/2015)... Texas (PRWEB) , ... August 28, 2015 , ... ... Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use ... Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound. ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced ... I study of BHV-0223, a glutamate modulating agent. ... BHV-0223 and recently obtained clearance from the U.S. ... human testing. Portage holds 54% equity interest in ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... 3 The Connecticut Technology,Council and UHY LLP is ... Connecticut. The list of winning companies, called the UHY ... revenue growth over the last four,years. Companies considered for ... of the public companies winning this year exceeding,$1Billion in ...
... MS, EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... U.S. pivotal phase III MAESTRO-03 trial of dirucotide ... a safety analysis,and recommended that the trial continue ...
... for Ap3ana, CTI,s ,personalized medicine, venture, SEATTLE, ... CTIC ) announced today that Christina A. Waters, ... Tyr Pharma and formerly Director of,Scientific Development at ... named President of CTI Europe. Based in Bresso, ...
Cached Biology Technology:Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners 2BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4
Form: Concentrated Applications: ELISA...
Form: Concentrated Applications: ELISA...
ANTI S. GROUP AG:H...
... Flp-In System creates isogenic cell lines ... of the protein of interest. This ... 3. In this experiment the coding ... subcloned into pcDNA5/FRT and transfected into ...
Biology Products: